Transcatheter mitral valve replacement or repair for secondary mitral regurgitation: a propensity score-matched analysis.
Functional mitral regurgitation
Secondary mitral regurgitation
Transcatheter edge-to-edge repair
Transcatheter mitral valve replacement
Journal
European journal of heart failure
ISSN: 1879-0844
Titre abrégé: Eur J Heart Fail
Pays: England
ID NLM: 100887595
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
revised:
05
02
2023
received:
13
11
2022
accepted:
08
02
2023
medline:
31
3
2023
pubmed:
9
3
2023
entrez:
8
3
2023
Statut:
ppublish
Résumé
This study aimed to compare outcomes after transcatheter mitral valve replacement (TMVR) and mitral valve transcatheter edge-to-edge repair (M-TEER) for the treatment of secondary mitral regurgitation (SMR). The CHOICE-MI registry included 262 patients with SMR treated with TMVR between 2014 and 2022. The EuroSMR registry included 1065 patients with SMR treated with M-TEER between 2014 and 2019. Propensity score (PS) matching was performed for 12 demographic, clinical and echocardiographic parameters. Echocardiographic, functional and clinical outcomes out to 1 year were compared in the matched cohorts. After PS matching, 235 TMVR patients (75.5 years [70.0, 80.0], 60.2% male, EuroSCORE II 6.3% [interquartile range 3.8, 12.4]) were compared to 411 M-TEER patients (76.7 years [70.1, 80.5], 59.0% male, EuroSCORE II 6.7% [3.9, 12.4]). All-cause mortality was 6.8% after TMVR and 3.8% after M-TEER at 30 days (p = 0.11), and 25.8% after TMVR and 18.9% after M-TEER at 1 year (p = 0.056). No differences in mortality after 1 year were found between both groups in a 30-day landmark analysis (TMVR: 20.4%, M-TEER: 15.8%, p = 0.21). Compared to M-TEER, TMVR resulted in more effective mitral regurgitation (MR) reduction (residual MR ≤1+ at discharge for TMVR vs. M-TEER: 95.8% vs. 68.8%, p < 0.001), and superior symptomatic improvement (New York Heart Association class ≤II at 1 year: 77.8% vs. 64.3%, p = 0.015). In this PS-matched comparison between TMVR and M-TEER in patients with severe SMR, TMVR was associated with superior reduction of MR and superior symptomatic improvement. While post-procedural mortality tended to be higher after TMVR, no significant differences in mortality were found beyond 30 days.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
399-410Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2023 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet. 2006;368:1005-11.
Goliasch G, Bartko PE, Pavo N, Neuhold S, Wurm R, Mascherbauer J, et al. Refining the prognostic impact of functional mitral regurgitation in chronic heart failure. Eur Heart J. 2017;39:39-46.
Bartko P, Pavo N, Pérez-Serradilla A, Arfsten H, Neuhold S, Wurm R, et al. Evolution of secondary mitral regurgitation. Eur Heart J Cardiovasc Imaging. 2018;19:622-9.
Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2022;43:561-632.
Coats A, Anker S, Baumbach A, Alfieri O, von Bardeleben R, Bauersachs J, et al. The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC. Eur Heart J. 2021;42:1254-69.
Otto C, Nishimura R, Bonow R, Carabello B, Erwin J, Gentile F, et al. 2020 ACC/AHA Guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;143:E72-E227.
Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM, et al. COAPT Investigators. Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med. 2018;379:2307-18.
Dziadzko V, Clavel M, Dziadzko M, Medina-Inojosa J, Michelena H, Maalouf J, et al. Outcome and undertreatment of mitral regurgitation: a community cohort study. Lancet. 2018;391:960-9.
Nishimura R, Vahanian A, Eleid M, Mack M. Mitral valve disease - current management and future challenges. Lancet. 2016;387:1324-34.
Urena M, Vahanian A, Søndergaard L. Patient selection for transcatheter mitral valve implantation: why is it so hard to find patients? EuroIntervention. 2018;14:AB83-90.
Muller D, Farivar R, Jansz P, Bae R, Walters D, Clarke A, et al.; Tendyne Global Feasibility Trial Investigators. Transcatheter mitral valve replacement for patients with symptomatic mitral regurgitation: a global feasibility trial. J Am Coll Cardiol. 2017;69:381-91.
Bapat V, Rajagopal V, Meduri C, Farivar R, Walton A, Duffy S, et al.; Intrepid Global Pilot Study Investigators. Early experience with new transcatheter mitral valve replacement. J Am Coll Cardiol. 2018;71:12-21.
Hungerford SL, Bart NK, Song N, Jansz P, Dahle G, Duncan A, et al. Transcatheter mitral valve edge-to-edge repair versus transapical mitral valve replacement in patients with LV dysfunction. JACC Cardiovasc Imaging. 2022;15:1514-6.
Ben Ali W, Ludwig S, Duncan A, Weimann J, Nickenig G, Tanaka T, et al.; CHOICE-MI Investigators. Characteristics and outcomes of patients screened for transcatheter mitral valve implantation: 1-year results from the CHOICE-MI registry. Eur J Heart Fail. 2022;24:887-98.
Koell B, Orban M, Weimann J, Kassar M, Karam N, Neuss M, et al.; EuroSMR Investigators. Outcomes stratified by adapted inclusion criteria after mitral edge-to-edge repair. J Am Coll Cardiol. 2021;78:2408-21.
Muller DWM, Sorajja P, Duncan A, Bethea B, Dahle G, Grayburn P, et al. 2-Year outcomes of transcatheter mitral valve replacement in patients with severe symptomatic mitral regurgitation. J Am Coll Cardiol. 2021;78:1847-59.
Reichart D, Kalbacher D, Rübsamen N, Tigges E, Thomas C, Schirmer J, et al. The impact of residual mitral regurgitation after MitraClip therapy in functional mitral regurgitation. Eur J Heart Fail. 2020;22:1840-8.
Sorajja P, Vemulapalli S, Feldman T, Mack M, Holmes DR, Stebbins A, et al. Outcomes with transcatheter mitral valve repair in the United States: an STS/ACC TVT registry report. J Am Coll Cardiol. 2017;70:2315-27.
Lim DS. Contemporary outcomes with MitraClipTM (NTR/XTR) System in primary mitral regurgitation: results from the Global EXPAND study. Tailoring Mitral Valve Repair. 2020. https://www.crtonline.org/presentation-detail/contemporary-outcomes-with-mitracliptm-ntr-xtr-sys (last accessed 20 January 2023).
Mack M, Carroll JD, Thourani V, Vemulapalli S, Squiers J, Manandhar P, et al. Transcatheter mitral valve therapy in the United States: a report from the STS-ACC TVT registry. J Am Coll Cardiol. 2021;78:2326-53.
Hensey M, Brown RA, Lal S, Sathananthan J, Ye J, Cheung A, et al. Transcatheter mitral valve replacement: an update on current techniques, technologies, and future directions. JACC Cardiovasc Interv. 2021;14:489-500.
Zahr F, Song HK, Chadderdon SM, Gada H, Mumtaz M, Byrne T, et al. Thirty-day outcomes following transfemoral transseptal transcatheter mitral valve replacement: Intrepid TMVR Early Feasibility Study results. JACC Cardiovasc Interv. 2021;15:80-9.
Pagnesi M, Moroni F, Beneduce A, Giannini F, Colombo A, Weisz G, et al. Thrombotic risk and antithrombotic strategies after transcatheter mitral valve replacement. JACC Cardiovasc Interv. 2019;12:2388-401.
Blackstone EH, Suri RM, Rajeswaran J, Babaliaros V, Douglas PS, Fearon WF, et al. Propensity-matched comparisons of clinical outcomes after transapical or transfemoral transcatheter aortic valve replacement: a placement of aortic transcatheter valves (PARTNER)-I trial substudy. Circulation. 2015;131:1989-99.
Webb J, Cheung A, Dvir D. Transcatheter mitral valve replacement when mitral surgery fails: 10 years later. J Am Coll Cardiol. 2017;70:1132-4.
Brener M, Grayburn P, Lindenfeld J, Burkhoff D, Liu M, Zhou Z, et al. Right ventricular-pulmonary arterial coupling in patients with HF secondary MR: analysis from the COAPT trial. JACC Cardiovasc Interv. 2021;14:2231-42.
Ludwig S, Sedighian R, Weimann J, Koell B, Waldschmidt L, Schäfer A, et al. Management of patients with mitral regurgitation ineligible for standard therapy undergoing TMVI screening. EuroIntervention. 2022;18:213-23.
Chhatriwalla AK, Vemulapalli S, Szerlip M, Kodali S, Hahn RT, Saxon JT, et al. Operator experience and outcomes of transcatheter mitral valve repair in the United States. J Am Coll Cardiol. 2019;74:2955-65.